Ignite Creation Date:
2024-05-05 @ 5:35 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00485758
Status:
COMPLETED
Last Update Posted:
2015-10-12
First Post:
2007-06-12
Brief Title:
Extended NiacinLaropiprant in Patients With Type 2 Diabetes 0524A-069
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Multicenter Randomized Double-Blind Placebo Controlled 36 Week Study to Evaluate the Efficacy and Safety of Extended Release ER NiacinLaropiprant in Patients With Type 2 Diabetes
Status:
COMPLETED
Status Verified Date:
2015-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A study to assess the efficacy and tolerability of ER Extended Release niacinlaropiprant versus placebo in Type 2 Diabetes Mellitus patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2007_543 | None | None | None |
| MK0524A-069 | None | None | None |